Havana, Oct. 21. -The Biotechnology Havana 2010 Congress opened in this capital on Wednesday with 130 experts from 27 countries, and is focused on comprehensive care for diabetic foot ulcer patients.
That condition is mostly treated in Cuba with Heberprot-P, a medicine created by the Genetic Engineering and Biotechnology Center, which sponsors the congress.
Four years after it was launched onto the market, the results of post-commercialization studies of that medicine will be discussed by roundtables, seminars, and workshops at the congress, which concludes on Friday.
The opening program includes the lectures Biotechnology Development in Cuba, by Cuban scientist Luis Herrera, and Epidermal Growth Factor, From the Lab to the Clinic, by the leader of the project, Jorge Berlanda, as well as other important papers.
Another symposium to be held is Epidermal Growth Factor, Molecular Biology, Toxicology, Pharmacogenomics, and Pre-clinic Trials, headed by Berlanda.
Heberprot-P is a cytoprotective agent that stimulates the formation of scar tissue. Its active principle is recombinant human epidermal growth factor, which restores homeostasis and the local immune response.
The medicine is patented in Argentina, Argelia, Venezuela, and Uruguay, Mexico, the United States, South Africa, Australia, India, and European countries such as Russia and Ukraine. (Prensa Latina)